HeimBNTX • NASDAQ
add
BioNTech SE - ADR
90,84 $
Fyrir opnun:(0,90%)-0,82
90,02 $
Lokað: 12. mar., 00:17:34 GMT-4 · USD · NASDAQ · Lagalegir fyrirvarar
Við síðustu lokun
83,89 $
Dagbil
86,28 $ - 92,59 $
Árabil
79,52 $ - 123,98 $
Markaðsvirði
23,53 ma. USD
Meðalmagn
1,09 m.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (EUR) | des. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 907,40 m. | -23,75% |
Rekstrarkostnaður | 907,20 m. | 15,13% |
Nettótekjur | -305,00 m. | -217,53% |
Hagnaðarhlutfall | -33,61 | -254,10% |
Hagnaður á hvern hlut | -0,33 | -130,56% |
EBITDA | -266,95 m. | -195,92% |
Virkt skatthlutfall | — | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (EUR) | des. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 13,74 ma. | -13,28% |
Heildareignir | 21,99 ma. | -2,40% |
Heildarskuldir | 2,76 ma. | -11,36% |
Eigið fé alls | 19,22 ma. | — |
Útistandandi hlutabréf | 244,20 m. | — |
Eiginfjárgengi | 1,07 | — |
Arðsemi eigna | -3,49% | — |
Ávöxtun eigin fjár | -3,96% | — |
Peningaflæði
Breyting á handbæru fé
| (EUR) | des. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -305,00 m. | -217,53% |
Handbært fé frá rekstri | 309,50 m. | 166,80% |
Reiðufé frá fjárfestingum | -2,73 ma. | -549,25% |
Reiðufé frá fjármögnun | -14,30 m. | -95,89% |
Breyting á handbæru fé | -2,42 ma. | -1.860,74% |
Frjálst peningaflæði | — | — |
Um
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Framkvæmdastjóri
Stofnsett
2008
Vefsvæði
Starfsfólk
6.772
